Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Net Margin
Catalyst Pharmaceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
2.5B USD |
37%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.6B USD |
6%
|
|
| US |
U
|
US BioTec Inc
OTC:USBC
|
172.5B USD | N/A | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
155.2B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
141.8B USD |
22%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
99.7B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
104.4B AUD |
19%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.9B USD |
31%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
58.1B USD |
-13%
|
Catalyst Pharmaceuticals Inc
Glance View
Catalyst Pharmaceuticals Inc., a biopharmaceutical company founded with a determined focus on developing innovative therapies, has systematically carved out a niche in the treatment of rare neuromuscular and neurological diseases. Headquartered in Coral Gables, Florida, the company emerged as a lifeline for patients grappling with these debilitating conditions, particularly targeting those with limited treatment options. At the heart of Catalyst’s business model is its flagship product, Firdapse (amifampridine), a pioneering medication approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). This niche focus allows Catalyst to not only address unmet medical needs but also to navigate a less crowded competitive landscape, where larger pharmaceutical giants often overlook rare conditions. Catalyst Pharmaceuticals' revenue stream is primarily derived from the commercial sales of Firdapse, which has gained traction in the rare disease market due to its status as a first-line treatment. The company adopts a strategic approach by exclusively concentrating on rare diseases, benefiting from incentives such as orphan drug designations, which often include extended market exclusivity, tax credits, and potential grants. This strategy is bolstered by an experienced management team that adeptly leverages Catalyst’s research capabilities and regulatory know-how, ensuring a robust pipeline poised for future growth. By maintaining strong relationships with healthcare providers and patient advocacy groups, Catalyst Pharmaceuticals reinforces its commitment to patient-centric solutions, enabling both sustained market presence and organic growth within its specialized field.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Catalyst Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of 37.4%.
You don't have any saved screeners yet